[Federal Register: November 15, 2004 (Volume 69, Number 219)]
[Notices]
[Page 65610-65611]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15no04-85]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Infectious Clone of Human Parvovirus B19 and Methods of Use
Ning Zhi et al. (NHLBI).
U.S. Patent Application No. 10/887,770 filed 09 Jul 2004 (DHHS
Reference No.E-178-2004/0-US-01 and corresponding Canadian patent
application (DHHS Reference No. E-178-2004/0-CA-02).
Licensing Contact: Susan Ano; 301/435-5515; anos@mail.nih.gov.
This technology described in this patent application relates the
first reported infectious human parvovirus B19 clone, methods of
cloning the parvovirus B19 genome as well as other viral genomes that
have secondary DNA structures that are unstable in bacterial cells. The
infectious clone and methods of producing the same would be useful in
producing infectious virus, which can in turn be used, among other
things, to identify and develop therapeutic agents for treatment and/or
prevention of human parvovirus B19 infections. The infectious
parvovirus B19 clone is also available for licensing. Additional
information about this invention can be found in Virology 2004, 318(1),
142-152.
Immunogenic Compositions for Eradication of Latent HIV
Genoveffa Franchini et al. (NCI).
U.S. Provisional Application No. 60/536,467 filed 13 Jan 2004 (DHHS
Reference No. E-072-2004/0-US-01); U.S. Provisional Application No. 60/
536,976 filed 16 Jan 2004 (DHHS Reference No. E-072-2004/1-US-01).
Licensing Contact: Susan Ano; 301/435-5515; anos@mail.nih.gov.
HIV infects CD4+ cells and, after incorporation of the viral genome
into the host genome, can either produce infectious virus or remain
latent. HIV that is latent presents a challenge for complete removal of
the virus in infected individuals and is becoming an increasingly
important consideration in the identification of potential therapeutics
or treatment regimens. This patent application describes immunogenic
compositions based on inhibiting the function of p28TEV
protein, the first protein expressed during HIV infection, for
treatment of latent HIV infection. Specifically, these compositions
include the p28TEV polypeptide, a polypeptide with
significant sequence homology to p28TEV, or immunogenic
fragments of these polypeptides. Additional compositions include
antibodies and other compounds that act to inhibit p28TEV
activity. This technology can also be utilized to detect latent HIV in
biological samples. These compositions and methods offer a potential
solution for complete virus eradication in therapeutic treatment of HIV
infected individuals.
Accelerated Vaccination Strategies To Provide Protection Against Viral
Infections
Gary J. Nabel et al. (NIAID).
U.S. Provisional Application No. 60/491,933 filed 01 Aug 2003 (DHHS
Reference No. E-317-2003/0-US-01); PCT Application filed on 01 Aug 2004
(DHHS Reference No. E-317-2003/0-PCT-02).
Licensing Contact: Susan Ano; 301/435-5515; anos@mail.nih.gov.
The technology described in this patent application relates to
recombinant viruses for use as vaccines. These viruses contain a single
or plurality of sequences encoding antigens from pathogenic viruses
[[Page 65611]]
heterologous to the recombinant virus. The antigenic sequences from
pathogens such as influenza, RSV, measles, HPV, Epstein-Barr, Lassa,
Polio, West Nile, Dengue, HIV-1 and 2, HTLV, herpes simplex virus,
hepatitis viruses A, B, C, D, and E, Marburg, Ebola, and SARS are
inserted into non-essential regions of either replication-competent or
replication-defective adenovirus, adeno-associated virus (AAV), SV40
virus, herpes simplex virus, or vaccinia virus vectors that retain
elements necessary for infectivity but are devoid of any pathogenic
sequence elements. In these recombinant viruses, the antigenic
sequences are operably linked to viral control elements. Thus, these
recombinant viruses are capable of infecting a host and mounting an
immune response specific to a given virus(es) without eliciting
pathogenicity. In addition to the above, the technology also describes
methods of accelerated pre-exposure or post-exposure vaccination
comprising single-dose administration. The attractive features of this
invention include the broad applicability of the recombinant viruses
against a number of common pathogens and the potential of using them
against other emergent infectious viruses; the ability of the vaccines
to stimulate both cellular and humoral immune responses in humans and
other hosts; and the ease of administration in single dose form via a
number of routes. This technology is now available for licensing. Some
fields of use may not be available.
Dated: November 9, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 04-25279 Filed 11-12-04; 8:45 am]
BILLING CODE 4140-01-P